• We studied laxative use and quality of life in persons with opioid-induced constipation (OIC).
Participants who respond "yes" to the question "have you ever experienced constipations while on opioid therapy such as less than three BM pr. week, bloating or pain in abdomen, BM too hard or straining/squeezing BM"
Introduction
Constipation is a well-known and common side-effect of opioid treatment in patients with moderate-to-severe pain. Between 40 and 70% of chronic opioid users suffer from opioid induced constipation (OIC) [1] [2] [3] [4] [5] .
A majority of patients experiencing symptoms of OIC, report that the OIC has negative impact on their general quality of life and every day activities [6] [7] [8] . In a recent study, more than 70% of the patients who receive opioids due to musculoskeletal pain, reported that they had not been informed about the risk of experiencing/developing OIC as a treatment side-effect [9] . Additionally, one-third of the patients had skipped doses, reduced or stopped their use of opioid therapy in order to resolve their gastrointestinal side effects, resulting in increased experience of pain for more than 90% of these patients [6] .
Real-life data on laxative utilization among patients suffering from OIC are very limited, and many patients suffering from OIC are only using over the counter laxatives to resolve their constipation.
In this cross-sectional survey study, the aim was to describe laxative utilization and quality of life in participants who ever experienced OIC.
Method

Study design and sample
This is a cross-sectional survey study among participants experiencing self-reported OIC. The online survey was conducted in collaboration with a pharmacy chain (Boots A/S, Norway), administering the survey via e-mail to more than 82,000 individuals who had indicated an interest in receiving general information from the pharmacy. Participants had to (1) confirm that they had been on opioid therapy for a minimum of 4 weeks with an expectation to continue for at last 3 months (to ensure participants were consistently treated with opioid e.g. not acute injury or post-surgical use), (2) actively accept participation in the study to get online access to the self-reported questionnaire, and (3) the participants had to confirm ever experiencing constipation while on opioid therapy. The study eligibility criteria are presented in Table 1 .
Data collection
All participants were informed that participation was voluntary and anonymous, and they gave consent to the collection, use, and disclosure of their online response. No data were collected that potentially could identify a person such as date of birth, name or personal identification number. The online survey took approximately 10 min to complete and comprised a series of multiple choice, close-ended, and free text questions which was divided in two parts, symptoms and treatment and health related quality of life. Data were collected between 27th of June 2014 and 3rd of July 2014.
Initially, eligible participants were asked if they were currently experiencing constipation while on opioid therapy, those who confirmed current constipation were then asked to evaluate the severity (no, mild, moderate, severe or very severe) of the following three common symptoms of OIC: abdominal pain, abdominal bloating, and pain on/during bowel movements.
Eligible participants were asked about management of their OIC, and their responses were categorized into: consulted health care professional (HCP; e.g., physician or nurse); consulted pharmacy without contacting HCP; self-management (e.g., bought over-thecounter laxative, reduced dose of opioid, changed opioid, or other) without contacting a HCP or pharmacy; or other/did nothing.
Participants who reported that they consulted a HCP or a pharmacy were then asked if they were advised to buy laxative with or without a prescription.
• Prescribed laxative users were defined as those who were advised by a HCP or pharmacy to buy prescribed laxative.
• Non-prescribed laxative users were defined as those who were advised by HCP or pharmacy to buy laxative without prescription and those who bought laxative without contacting a HCP or a pharmacy.
Both prescribed and non-prescribed laxative users were asked to specify what type of laxatives they bought: macrogol 3350/potassium chloride/sodium bicarbonate/sodium chloride, lactulose, bisacodyl, senna, ispaghula, other. Further, all laxative users were categorized according to number of different brands of laxatives used (one laxative, two or more laxatives), frequency of laxative use (daily; 6-3 days/week; 1-2 days/week; <1 day/week), and self-rated satisfaction with laxative on a 5-point scale from very satisfied to very dissatisfied.
Health related quality of life was assessed by means of the Euro-QOL 5 Dimensions (EQ-5D) [10] which is a validated 5-item health state descriptive system where full health is one, and zero is equivalent to death (EQ-5D index) and a visual analogue scale (EQ-5D VAS, range 0-100 from worst to best imaginable health state).
Statistical methods
Continuous variables are presented as means and standard deviations and categorical variables as absolute and relative frequencies. Statistical comparisons were made using analysis of variance (ANOVA) for continuous variables and chi-square test for categorical variables. The significance level is set at 5% but as no adjustment for multiplicity has been performed the p-values should be considered as exploratory.
Ethical conduct
An opinion was obtained from Regional Committees for Medical and Health Research Ethics (REC) in writing (reference number: 2013/2405 D) stating that the project did not need to be submitted to ethics Committee due to its design and purpose.
Results
A total of 910 participants confirmed that they had been treated with opioids for a minimum of 4 weeks with the expectation to continue for at least 3 months. About half of the participants (n = 445) confirmed that they had at some point experienced OIC and therefore were eligible for data analysis. Excluding 28 participants who did not complete the survey, this study counted 417 eligible participants who completed the first part of the survey.
Among the 417 eligible participants who reported ever experienced OIC, 86% were females and 85% were younger than 60 years old (Table 2) . Further, more than half of the participants (57%) were currently suffering constipation while on opioid therapy ( Table 2 ). The participants responded to questions regarding how they managed their OIC, and less than every fourth participant (23%) had consulted health care professional (i.e., physician or nurse). Thirty-nine percent reported that they handled their OIC by self-management, e.g., bought laxative, reduced the dose and/or changed opioid without consulting HCP or pharmacy. Twentythree percent reported that they had used two or more laxatives, 34% had used one laxative, and 43% had not used laxative.
The most frequently used opioid therapy was codein/paracetamol followed by tramadol hydrochloride, tramadol hydrochloride/paracetamol (Fig. 1) . The most frequently used laxative was lactulose followed by bisacodyl (Fig. 2) .
More than half of the 239 particpants on opioid therapy who were currently constipated were experiencing moderate to very severe symptoms related to OIC. Severe to very severe symptoms were observed in 16% suffering from abdominal bloating, 12% suffered from pain during bowel movement, and 8% who had abdominal pain. The symptom burden was more prevalent in currently constipated participants using laxatives compared to non-laxative users (Fig. 3) . The most pronounced difference in prevalence of moderate to very severe symptom was found for abdominal bloating when comparing participants using no (46%), one (64%), and two or more laxatives (90%) (p < 0.05).
The laxative utilization among the 236 laxative users who ever experienced OIC is presented in Table 3 . Twelve percent of the laxative users reported that they purchased laxative which was prescribed by their HCP. Almost two of three (62%) prescribed laxative users reported that they had tried only one laxative. However, it was reported that more than one-third (34%) of the prescribed laxatives users had previously tried non-prescribed laxative. Participants using two or more laxatives were generally using them more frequently than those using only one laxative (daily use of laxative: 21% and 6%, respectively). Less than half (48%) of the laxative users were satisfied with the laxative they were using, one-third (34%) were neither satisfied or dissatisfied, and about one-fourth (18%) reported that they were dissatisfied with the laxative they were using.
The response rate for the second part of the survey decreased due to technical issues (users of iOS (Ipad and Iphone) were not able to get access to EQ5-D questionnaire), therefore only 188 of the eligible participants were able to answer the items on healthrelated quality of life. The EQ-5D index and the EQ-5D VAS score according to currently constipated, use of laxative, prescription, laxative frequency, and satisfaction are presented in Table 4 . The mean EQ-5D index score was 0.587 (SD: 0.272) and the mean EQ-5D VAS score was 60.7 (SD: 22.6). Although not statistically significant (p = 0.067), there was a tendency of lower health-related quality of life among the participants who were currently constipated compared to those not currently constipated (difference of means: 0.629-0.555 = 0.074). The lowest health-related quality of life was found among participants who were dissatisfied with their laxative (mean EQ-5D index: 0.424; mean EQ-5D VAS score: 46.1), and statistically significant lower than for those who were satisfied and those who were neither satisfied nor dissatisfied with laxative (EQ-5D index: p = 0.001 and EQ-5D VAS score: p = 0.004).
Discussion
The results from this cross-sectional survey study among participants experiencing OIC suggest a high degree of moderate to very severe abdominal symptoms, a high degree of self-management of OIC, a relatively low degree of satisfaction with laxatives, and low health-related quality of life, especially among those using more laxatives and using laxatives more often.
Our results show that more than half of the currently constipated participants reported having moderate to very severe abdominal symptoms (i.e., pain in abdomen, pain during bowel movement, and abdominal bloating). This finding was similar to the prevelence of these symptoms reported by Coyne et al. [7] in a sample of patients recruited from primary care clinics. Some of these common abdominal symptoms, particularly bloating, might also occur as side effects of several classes of laxatives [11] . The high usage of over-the-counter lactulose in Norway is especially an unfortunate tradition because of its high prevalence of its adverse effects bloating and abdominal discomfort and even abdominal pain. Indeed, the symptom burden was more prevalent in laxative users than in non-laxative users in our study, particulary abdominal bloating among participants who have used two or more laxatives. However, the relatively high prevalence of these symptoms might also suggest that for the participants who have used two or more laxatives the currently utilized laxative therapies may be lacking in efficacy and tolerability as well as there is a possibility that participants who are not using laxatives are undertreating their OIC. In a recent longitudinal study by Coyne et al. [12] with prospective data from US, Canada, Germany, and UK it was estimated that more than one of four participants was a sufficient laxative user but at the same time inadequate laxative responders, defined as <3 bowel movements or ≥1 moderate to very severe constipation symptom.
Self-management of OIC was frequent among the participants in our study. More than two out of five participants reported that in order to handle their OIC they had bought laxative, reduced the daily dose and/or changed opioid without consulting their HCP or [13] . In a recent Danish crosssectional study among patients filling prescriptions for opioids at a community pharmacy, Pottegård et al. [9] concluded that only few of the participants (28%) recalled having had information on potential constipation caused by opioid and having received any recommendation on how to use laxatives to prevent constipation.
The fact that relatively few (23%) of the participants in our study had consulted their physician or nurse regarding how to manage their OIC imply that they might be unaware of recent advances in therapeutic approaches for OIC to manage and prevent OIC without compromising analgesic efficacy [14] . Furthermore, our results show that less than half (48%) of the laxative users were satisfied with their laxative and almost Fig. 2 . Frequency of different types of laxatives used among participants who ever experienced OIC and had used laxative, n = 236.
a Macrogol 3350/potassium chloride/sodium bicarbonate/sodium chloride. one-quarter reported dissatisfaction with the laxative they were using, which is consistent with the proportion reported in Cook et al. [13] .
Generally the health-related quality of life (QoL) reported by the participants in our study was relatively low with a mean EQ-5D index score of 0.587. Our results support the finding reported by Brazier et al. [15] in a sample of seven different patient groups (chronic obstructive airways disease, osteoarthritis, irritable bowel syndrome, lower back pain, leg ulcers, post-menopausal women and elderly) in UK, in which the overall mean EQ-5D index score was 0.586. However, in that study the mean EQ-5D index score varied across the seven patient/population groups from 0.442 in osteoporosis patients to 0.729 in menopausal women. In the study by Coyne et al. [7] evaluating currently constipated opioid users, the mean EQ-5D index score varied across the four country-specific samples from 0.270 in UK to 0.610 in Canada. A number of studies have shown that patients with constipation report lower QoL than non-constipated individuals [16] [17] [18] [19] which is consistent with our results, although not statistically significant, participants who were currently constipated had a lower QoL than those who were not currently constipated (mean EQ-5D index score 0.555 and 0.629, respectively). In addition, our study adds to the literature, that the lowest QoL was found among participants who were dissatisfied with their laxative and participants who used laxatives every day (mean EQ-5D index score 0.424 and 0.497, respectively). Similar patterns were reflected by the mean EQ-5D VAS.
This patient group undoubtedly will benefit from more specific therapy that is now being introduced. Peripherally acting opioid receptor antagonist (PAMORAs) has recently been documented to be effective and safe for this group of unfortunate chronic pain patients needing opioid for their pain condition [20] . Such drugs will avoid the extra burden imposed on chronic pain patients who frequently have had to use two or more types of laxatives with extra burden of side-effects/adverse effects of such laxatives.
Limitations and strengths
As with other survey based evaluations, the present study comes with some limitations to be taken into account when interpreting the results. First, we were unable to compare the observed use of laxative among patients treated with opioids to an age-matched control group not treated with opioids.
Second, our study sample was drawn from an online database established by a pharmacy chain (Boots A/S, Norway) which could have biased the sample towards participants having a greater familiarity with the Internet and interest in receiving information from the pharmacy. Although, the age and gender distribution were skewed in favour of younger and female participants, potentially inferring low generalizability and external validity, the results still are well in accordance with previous studies on symptom burden, self-management, and quality of life in relation to OIC.
Third, the questions, except of EQ-5D, were defined for the present study only, and were thus not validated or standardized. Also, data analyzed in this study was based exclusively on self-report and may be subject to inaccuracy or recall bias.
Fourth, the participants may be taking other medications, have limited mobility or have dietary habits that contribute to constipation. Therefore, it may not be certain that the OIC symptoms found in this study are only related to opioids.
This study also comes with strengths, not the least the use of an anonymized self-administration questionnaire. This may have allowed a more honest response to sensitive questions related to symptoms and self-management of constipation as opposed to an interviewer-administration questionnaire, which may induce a social desirability response bias where the respondent seeks to please the interviewer. Further, since there are no registries in the Nordic countries capturing over the counter drug use, conducting the study via a pharmacy chain database enabled assessment of utilization of these types of easily accessible laxatives. In addition, this study not only sheds light on the prevalence and use of laxative but also explore aspects of symptoms and health-related quality of life in both non-laxative and laxative users.
Conclusions and implications
The results from this cross-sectional survey study among participants experiencing OIC suggest a high degree of moderate to very severe abdominal symptoms, a high degree of self-management of OIC, a low degree of satisfaction with laxatives, and low health-related quality of life of patients suffering from chronic pain necessitating long-term opioid treatment. This implies that patients suffering from OIC with low quality of life and remaining symptoms despite use of two or more laxative are a vulnerable patient group in need of optimized healthcare management, who also might benefit from more specific and innovative therapy.
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